Effect of Pioglitazone on Insulin Resistance and Atherosclerosis in Renal Allograft Recipients Without Diabetes
The aim of this study was to evaluate the effect of pioglitazone treatment on insulin secretion, insulin resistance, and progression of atherosclerosis in renal allograft recipients without preoperative history of diabetes.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||A Randomized Controlled Trial of Pioglitazone on Insulin Resistance, Insulin Secretion and Atherosclerosis in Renal Allograft Recipients Without History of Diabetes|
- Insulin Resistance and Insulin Secretion [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- carotid intima-media thickness [ Time Frame: 1 year ] [ Designated as safety issue: No ]
|Study Start Date:||November 2004|
|Study Completion Date:||November 2007|
|Primary Completion Date:||November 2007 (Final data collection date for primary outcome measure)|
The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
|No Intervention: 2|
This is a prospective, randomized, open-label study. The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
After treatment, we estimated insulin sensitivity index for transplantation,first phase and second phase insulin secretion, secretion area under the curve,and carotid intima-media thickness.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00598013
|Korea, Republic of|
|Yonsei University College of Medicine|
|Seoul, Korea, Republic of, 120-752|
|Principal Investigator:||Hyun Chul Lee, Doctor||Yonsei University|